Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results

Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results

Aim of investigation. Primary objective: to estimate the prevalence of NAFLD within the general practitioner’s and gastroenterologist’s patient flow.Materials and methods. The prospective disease registry was carried out as epidemiologic, observational, cross-sectional, multicenter investigation to...

Full description

Saved in:

Bibliographic Details
Main Authors:	V. T. Ivashkin, O. M. Drapkina, I. V. Mayev, A. S. Trukhmanov, D. V. Blinov, L. K. Palgova, V. V. Tsukanov, T. I. Ushakova
Format:	Article
Language:	Russian
Published:	Gastro LLC 2015-12-01
Series:	Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:	direg 2, epidemiology, nafld, nonalcoholic fatty liver disease, nash, non-alcoholic steatohepatitis, prevalence
Online Access:	https://www.gastro-j.ru/jour/article/view/1036
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A New Hope for the Patients of Non‐Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use
by: Abdul Haseeb Hasan, et al.
Published: (2025-01-01)

Two faces of the same coin non alcoholic fatty liver disease; with and without diabetes: Comparative clinico pathological analysis: A cross sectional observational study
by: Syed Mushfiq, et al.
Published: (2025-01-01)

Methodical approaches in experimental modelling of non-alcoholic fatty liver disease
by: N. V. Bivalkevich, et al.
Published: (2015-09-01)

Association of nonalcoholic fatty liver disease and growth hormone deficiency: a systematic review and meta-analysis
by: Tingting Kong, et al.
Published: (2023-10-01)

Association of Breastfeeding with Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in mothers: A cross sectional survey
by: Muhammad Zafar Majeed Babar, et al.
Published: (2024-06-01)

Epidemiologic features of non-alcoholic fatty liver disease in Russia
by: O. M. Drapkina, et al.
Published: (2014-10-01)

Unraveling the Beneficial Role of Resveratrol in Fructose-Induced Non-Alcoholic Steatohepatitis with a Focus on the AMPK/Nrf2 Signaling Axis
by: Soha S. Zakaria, et al.
Published: (2025-01-01)

Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion
by: V. V. Tsukanov, et al.
Published: (2023-11-01)

The impact of the ursodeoxycholic acid as monotherapy and in the combination with the lactulose on the biochemical blood tests values of the nonalcoholic steatohepatitis patients
by: I. V. Mayev, et al.
Published: (2013-03-01)

Application of ursodeoxycholic acid at non-alcoholic and alcohol-induced steatohepatitis
by: Ye. A. Fedos’ina, et al.
Published: (2010-06-01)

New aspects of non-alcoholic fatty liver disease
by: V. V. Tsukanov, et al.
Published: (2015-09-01)

Combination of autoimmune hepatitis to non-alcoholic steatohepatitis (Clinical case)
by: A. A. Driga, et al.
Published: (2010-11-01)

The rationale for the aggressive progression of MASLD in patients with type 2 diabetes
by: Valeria Michelle Fernández-Garibay, et al.
Published: (2025-01-01)

Comparative Efficacy of NAFLD Therapies and Biomarker Associations: A Meta-Analysis Based on Liver Fat Content
by: Haoxiang Zhu, et al.
Published: (2025-01-01)

Non-Alcoholic Fatty Liver Disease, Bile Acids and Intestinal Microbiota
by: R. V. Maslennikov, et al.
Published: (2018-09-01)

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
by: D. V. Garbuzenko
Published: (2022-01-01)

Association Between Sociodemographic Variables, Healthy Habits, and Stress with Risk Scales for Liver Disease Associated with Metabolic Dysfunction
by: Ángel Arturo López-González, et al.
Published: (2025-01-01)

Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis
by: Like Zhou, et al.
Published: (2025-01-01)

Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Myrsini Orfanidou, et al.
Published: (2024-12-01)

Phenotypes of Non-Alcoholic Fatty Liver Disease in Different Regions of the Russian Federation, Diagnostic and Therapeutic Approach in Clinical Practice
by: V. T. Ivashkin, et al.
Published: (2023-08-01)

Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease
by: Roger F. Butterworth, et al.
Published: (2019-03-01)

Efficacy and Safety of Bicyclol Treatment for Non-Alcoholic Fatty Liver Disease: Results of a Cohort Study
by: I. Yu. Pirogova, et al.
Published: (2018-09-01)

Principles of management of patient with asymptomatic elevation of serum aminotransferases
by: Ye. N. German, et al.
Published: (2011-02-01)

FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
by: Muhammad Mazhar Azam, et al.
Published: (2024-12-01)

Detectability of Liver Steatosis and Fibrosis with Transient Elastography and Controlled Attenuation Parameter in Residents of St. Petersburg
by: V. P. Kovyazina, et al.
Published: (2021-04-01)

Profile of Children With Non-alcoholic Fatty Liver Disease Referred to a Hospital in Iran
by: Amin Ghanbari, et al.
Published: (2024-12-01)

Triglycerides mediate the relationships of per- and poly-fluoroalkyl substance (PFAS) exposure with nonalcoholic fatty liver disease (NAFLD) risk in US participants
by: Wenying Qiao, et al.
Published: (2025-01-01)

Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease
by: V. T. Ivashkin, et al.
Published: (2022-12-01)

CISD2-mediated mitochondrial dysfunction and iron redistribution contributes to ferroptosis in arsenic-induced nonalcoholic steatohepatitis
by: Jingyuan Zhang, et al.
Published: (2025-01-01)

Validation of the Chronic Liver Disease Questionnaire for MASH (CLDQ-MASH)
by: Zobair M. Younossi, et al.
Published: (2025-03-01)

Liver and Nutrition. An Optimal Diet for Non-Alcoholic Fatty Liver Disease
by: M. V. Mayevskaya, et al.
Published: (2018-11-01)

Association of GCKR and MBOAT7 genetic polymorphisms with non-alcoholic fatty liver disease
by: Swati U. Chavan, et al.
Published: (2024-03-01)

Improvement of non-alcoholic fatty liver disease treatment
by: P. I. Seliverstov, et al.
Published: (2014-10-01)

Ultrasound radiomics-based logistic regression model for fibrotic NASH
by: Fei Xia, et al.
Published: (2025-02-01)

Research of <i>PNPLA3</i> I148M Gene Polymorphism in Patients with Non-Alcoholic Fatty Liver Disease, with Liver Cirrhosis and with Hepatocellular Carcinoma
by: V. V. Petkau, et al.
Published: (2023-11-01)

Effects of laparoscopic sleeve gastrectomy on nonalcoholic fatty liver disease and TGF-β signaling pathway
by: Hideki Kumagai, et al.
Published: (2024-02-01)

A prediction model of liver fat fraction and presence of non-alcoholic fatty liver disease (NAFLD) among patients with overweight or obesity
by: Jie Chen, et al.
Published: (2023-10-01)

Targeted Plasma Bile Acid Metabolomic Analysis in Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Hepatitis
by: Yuta Hirata, et al.
Published: (2024-12-01)

A Study to Assess the Prevalence of Depression among Alcoholics, among Patients, Admitted to Christian Institute of Health Sciences and Research, Dimapur, Nagaland
by: Nukshijungla Ao
Published: (2023-12-01)

Role of plasma metabolome in mediating the effect of plasma lipidome on NAFLD: a Mendelian randomization study
by: Zhuyuan Zheng, et al.
Published: (2025-01-01)